Ochsner Health utilizes groundbreaking ablation system for atrial fibrillation
2024-04-09
(Press-News.org) New Orleans, LA – Ochsner Health is proud to bring an advancement in the treatment of heart rhythm disorders to the New Orleans and Gulf South region utilizing a new cardiac ablation procedure, the FARAPULSE™ Pulsed Field Ablation System. The innovative procedure was performed at the John Ochsner Heart & Vascular Institute, a frontrunner in cardiology that continues to set the standard for cardiovascular care through its commitment to pioneering breakthrough therapies.
With the estimated number of individuals affected by atrial fibrillation predicted to rise to 12.1 million in the United States by 2030 according to the CDC, the introduction of this new treatment option signals a pivotal shift in managing a condition that can lead to debilitating strokes and heart failure. Known as the most prevalent type of erratic heartbeat, atrial fibrillation accounts for more than 400,000 hospitalizations and contributes to over 150,000 deaths annually nationwide.
The new cardiac ablation therapy offers patients a novel therapeutic approach that prioritizes safety and efficacy. This technological breakthrough promises to redefine standard cardiac ablation treatments, ushering in an era of enhanced patient outcomes with fewer complications.
“We are proud to have performed the first cardiac ablation procedure in the New Orleans and Gulf South region using the FARAPULSE™ Pulsed Field Ablation System,” said Dr. Michael Bernard, interim section head of Electrophysiology & Arrhythmia, Ochsner Health. “The incidence of atrial fibrillation is on the rise, and such safe, effective and efficient therapies allow physicians to treat more patients, reduce complications, and benefit overall public health.”
Ochsner Health's Electrophysiology Lab, leading with innovative technology, strengthens the organization’s reputation for progress in cardiac care. With the largest electrophysiology lab and a diverse team of experts, Ochsner Health provides exceptional care for individuals with atrial fibrillation and heart rhythm disorders. Patients and families can find comfort in knowing that unparalleled cardiac care is within reach, delivered by a multi-disciplinary team of expert healthcare professionals.
"Innovation in healthcare is not just about introducing new treatments; it's about transforming lives,” said Dr. Sammy Khatib, chair, Department of Cardiology, Ochsner Health. “By bringing cutting-edge therapies to Ochsner Health, not only are we advancing medical science but also offering hope and improved outcomes to patients facing heart rhythm disorders. This commitment to innovation sets a new standard for cardiovascular care and underscores our dedication to revolutionizing healthcare delivery in the region."
For more information about Electrophysiology and Heart Rhythm Disorders and treatment at Ochsner Health, visit www.ochsner.org/services/electrophysiology-and-heart-rhythm-disorders.
###
About Ochsner Health
Ochsner Health is the leading not-for-profit healthcare provider in the Gulf South, delivering expert care at its 46 hospitals and more than 370 health and urgent care centers. For 12 consecutive years, U.S. News & World Report has recognized Ochsner as the No. 1 hospital in Louisiana. Additionally, Ochsner Children’s has been recognized as the No. 1 hospital for kids in Louisiana for three consecutive years. Ochsner inspires healthier lives and stronger communities through a combination of standard-setting expertise, quality and connection not found anywhere else in the region. In 2023, Ochsner Health cared for more than 1.5 million people from every state in the nation and 65 countries. Ochsner’s workforce includes more than 38,000 dedicated team members and over 4,700 employed and affiliated physicians. To learn more about how Ochsner empowers people to get well and stay well, visit https://www.ochsner.org/.
END
ELSE PRESS RELEASES FROM THIS DATE:
2024-04-09
Genetic studies of diseases map segments of the genome driving disease. But to understand how those changes contribute to disease progression, it is important to understand how they may alter gene regulation of disease genes in cell populations assumed to be driving disease. “Enhancer-gene maps” link genomic regulatory regions to genes and are essential for understanding disease. But constructing them poses challenges due to limitations in current experimental methods, that make it difficult to apply the technique to rare cell populations and genes that ...
2024-04-09
We all lose our car keys or our glasses from time to time. Most people would be correct to laugh it off as a normal part of aging. But for others, cognitive decline may start as a worrying but clinically unnoticeable step toward cognitive impairment, be it relatively mild or as severe as Alzheimer’s disease.
The vast complexity of the human brain makes early diagnosis of cognitive decline difficult to achieve, which has potentially important implications for treatment and prevention. This is especially true ...
2024-04-09
A clinical trial led by Weill Cornell Medicine investigators showed that a nasal spray that patients administer at home, without a physician, successfully and safely treated recurrent episodes of a condition that causes rapid abnormal heart rhythms. The study, published March 25 in the Journal of the American College of Cardiology, provides real-world evidence that a wide range of patients can safely and effectively use the experimental drug, called etripamil, to treat recurrent paroxysmal supraventricular ...
2024-04-09
In the last decade, the emergence of a massive expanse of Sargassum, the Great Atlantic Sargassum Belt, has wreaked havoc on ecosystems and economies throughout the Caribbean. Conversely, this stinky brown seaweed provides vital habitats for marine life including loggerhead sea turtles.
One of the worst invasions of Sargassum in recent history, especially for Florida, occurred in 2022 and potential impacts this year are yet to be determined. Decomposing Sargassum produces hydrogen sulfide and ammonia, which can result in potential human and environmental health impacts. Once Sargassum deluges beaches, removing, disposing and repurposing the seaweed presents many logistical ...
2024-04-09
URBANA, Ill. — In the quest to optimize crop productivity across environments, soybean breeders test new cultivars in multiple locations each year. The best-performing cultivars across these locations are selected for further breeding and eventual commercialization. However, a new study from the University of Illinois Urbana-Champaign suggests current soybean testing locations may not be delivering breeders the biggest bang for their buck.
“We met with most of the soybean breeders in public research universities across the Midwest and asked where they set up their trials over the last 30 to 40 years,” said Nicolas Martin, ...
2024-04-09
BIRMINGHAM, Ala. – Morphine and other opioids are vital to treat severe and chronic pain. However, they have two problems — prolonged use creates morphine tolerance, where ever-increasing doses are needed for the same pain relief, and paradoxically, prolonged use also can create an extreme sensitivity to pain, called hyperalgesia.
Researchers at the University of Alabama at Birmingham and Baylor College of Medicine, Houston, Texas, now have shown that blocking the activity of an enzyme called Tiam1 in certain ...
2024-04-09
Bedsores—also known as pressure injuries—are the fastest rising hospital-acquired condition, according to the U.S. Agency for Healthcare Research in Quality, and as a result have become the second most common reason for medical malpractice suits in the United States.
Although most hospital-acquired pressure injuries are reasonably preventable, approximately 2.5 million individuals in the United States develop a pressure injury in acute care facilities every year, and 60,000 die. The total annual cost for U.S. health systems to manage the acute needs of patients’ ...
2024-04-09
Alexandria, VA, USA – The International Association for Dental, Oral, and Craniofacial Research (IADR) has announced three recipients of the 2024 IADR LION Dental Research Award. The recipients were recognized during the Opening Ceremonies of the 102nd General Session of the IADR, which was held in conjunction with the 53rd Annual Meeting of the American Association for Dental, Oral, and Craniofacial Research and the 48th Annual Meeting of the Canadian Association for Dental Research, on March 13-16, 2024, in New Orleans, LA.
The recipients are:
Andrea Escalante Herrera
University of ...
2024-04-09
Alexandria, VA, USA – The International Association for Dental, Oral, and Craniofacial Research (IADR) has announced Cher Farrugia and Wei Qiao as the winners of the 2024 IADR STAR Network Academy Fellowship. Farrugia, from the University of Bristol, England, UK, and Qiao, from The University of Hong Kong, SAR, China, were recognized during the Opening Ceremonies of the 102nd General Session of the IADR, which was held in conjunction with the 53rd Annual Meeting of the American Association for Dental, Oral, and Craniofacial Research and the 48th Annual ...
2024-04-09
Alexandria, VA, USA – The International Association for Dental, Oral, and Craniofacial Research (IADR) has announced Fiorella Ventura as the winner of the 2024 IADR Norton Ross Fellowship. Ventura, from the University of Buenos Aires, Argentina, was recognized during the Opening Ceremonies of the 102nd General Session of the IADR, which was held in conjunction with the 53rd Annual Meeting of the American Association for Dental, Oral, and Craniofacial Research and the 48th Annual Meeting of the Canadian Association for ...
LAST 30 PRESS RELEASES:
[Press-News.org] Ochsner Health utilizes groundbreaking ablation system for atrial fibrillation
